Achieving the best of both worlds

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 3-4

  Ko, Andrew H ^a   Cella, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL PRACTICE; COLON CANCER; EDITORIAL; EMOTIONAL STRESS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MENTAL STRESS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN ASSESSMENT; PANCREAS CANCER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PHYSICAL STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RISK FACTOR; SENSORY NEUROPATHY; SOCIAL BEHAVIOR; SURVIVAL RATE; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; QUALITY OF LIFE;

EID: 84871752759     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4891     Document Type: Editorial

References (14)

1. Wittes J: The use of soft endpoints in clinical trials: The search for clinical significance, in Mesbah M, Cole BF, Lee M-LT (eds): Statistical Methods for Quality of Life Studies: Design, Measurements, and Analysis. Dordrecht, the Netherlands, Kluwer Academic Publishers, 2002, pp 129-140
2. O'Mara AM, Denicoff AM: Health related quality of life in NCI-sponsored cancer treatment trials. Semin Oncol Nurs 26:68-78, 2010
3. Morris J, Perez D, McNoe B: The use of quality of life data in clinical practice. Qual Life Res 7:85-91, 1998
4. Gotay CC, Korn EL, McCabe MS, et al: Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992
5. National Cancer Institute: NCI Dictionary of Cancer Terms: Quality of life. http://www.cancer.gov/dictionary?cdrid=45417
6. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
7. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31:23-29, 2013
8. Conroy T, Desseigne F, Ychou M, et al: Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:303s, 2010 (suppl 15; abstr 4010)
9. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
10. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
11. Gotay CC, Kawamoto CT, Bottomley A, et al: The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355-1363, 2008
12. Eton DT, Fairclough DL, Cella D, et al: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21:1536-1543, 2003
13. Lilenbaum RC, Cashy J, Hensing TA, et al: Prevalence of poor performance status in lung cancer patients: Implications for research. J Thorac Oncol 3:125-129, 2008
14. Philip PA, Mooney M, Jaffe D, et al: Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. J Clin Oncol 27:5660-5669, 2009